Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(CCTG) BR.36A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients with Non-Small Cell Lung CancerJuergens, Dr RosalynOpen to recruitmentNCT04093167
(CCTG) BRC.8/ SWOG S1827/ MAVERICKMRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)Swaminath, Dr AnandOpen to recruitmentNCT04155034
(HHS) LINNEARRE IPhase I study of neo-adjuvant stereotactic body radiotherapy (SBRT) in operable patients with borderline resectable locally advanced non-small cell lung cancer (NSCLC)Tsakiridis, Dr TheosOpen to recruitmentNCT02433574
(Janssen) 73841937NSC3003 / MARIPOSAA Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerJuergens, Dr RosalynOpen to recruitmentNCT04487080
(Merck) MK-7684A-003A Phase 3, Multi-center, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Co-formulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants with PD-L1 Positive (TPS ≥1%) Metastatic Non-Small Cell Lung CancerJuergens, Dr RosalynOpen to recruitmentNCT04738487
(Mirati) 516-005 / SAPPHIRERandomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in
Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)
Juergens, Dr RosalynOpen to recruitmentNCT03906071
(Novartis) CACZ885T2301A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer
Juergens, Dr RosalynOpen to recruitmentNCT03447769
(Merck) MK-3475-B99 / KEYNOTE B99A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive Stage Small Cell Lung CancerJuergens, Dr RosalynSuspended/On holdNCT04924101
Download PDF